NEW HAVEN, CT, and TORONTO, Nov. 13 /CNW/ - BioRelix, pioneers in the
discovery and development of RiboSwitch based therapeutic agents and Dalton
Medicinal Chemistry, have jointly announced a research collaboration to
discover new therapeutics.
Dalton Medicinal Chemistry will utilize their proprietary insights to
design and synthesize several novel classes of compounds against selected
RiboSwitch targets. BioRelix will advance these compounds using their cutting
edge battery of biological assays and thorough knowledge of RiboSwitch drug
discovery and development.
Brian Dixon, BioRelix CEO commented: "We are pleased to have the
opportunity to work with the creative team at Dalton Medicinal Chemistry in
the discovery of new entities for treating infectious diseases. Their
expertise, coupled with our proprietary and leading position in RiboSwitch
technology will lead to important new medicines."
Judd Berman, Co-founder of Dalton Medicinal Chemistry, said: "We are
delighted to have this opportunity to work with BioRelix in the discovery of
much needed new anti-infective agents. The team at BioRelix has clearly
established an exceptionally innovative approach to anti-infectives."
BioRelix Pharmaceuticals, Inc. is a drug discovery and development
company focused on identifying new anti-infective drug treatments. BioRelix is
building a portfolio of anti-infective products based on novel patented RNA
targets, termed RiboSwitches, which were identified in the laboratory of
BioRelix co-founder, Ronald Breaker Ph.D., Howard Hughes Investigator and
Henry Ford II Professor at Yale University. BioRelix investors include CHL
Medical Partners, New Leaf Venture Partners, Aisling Capital, Novartis Venture
Fund, Elm Street Ventures and Alexandria Real Estate Equities.
About Dalton Pharma Services
Dalton Chemical Laboratories Inc. o/a Dalton Pharma Services is a Health
Canada approved contract pharmaceutical manufacturer that supplies chemistry
and analytical services to the biotechnology and pharmaceutical industries in
the areas of chemistry, medicinal chemistry and fine chemical manufacture.
Dalton provides cGMP manufacturing and sterile filling services to its
customers at any stage of the regulatory process (Phase I, II, III or
commercial). In its state of the art cGMP facilities, Dalton produces active
pharmaceutical ingredients at the gram or kilogram scale. Dalton conducts
sterile fills to produce batches of finished drug product in vials or
syringes, either aseptically filled or terminally sterilized, under fully
validated conditions. In addition, Dalton's analytical chemistry laboratory
offers method development, validation and ICH stability programs to its
For further information:
For further information: BioRelix, Inc., Brian R. Dixon, (203) 785-9282,
www.biorelix.com; Dalton Pharma Services, Peter Pekos, (416) 661-2102,